1. BP1401 is an agonist for toll-like receptor 9 (TLR9), which is an immunoregulatory factor that turns cold tumors into hot tumors.

While most drugs marketed or developed by other pharma companies are administered directly and topically to tumors, BP1401 can be intravenously administered and is therefore expected to safely bring systemic effects. This feature is realized by using lipid nanoparticle (LNP) as a drug delivery system.


BP1401 stimulates receptors (TLR9) on dendritic cells to help activate antitumor T cells in an immunosuppressive tumor microenvironment.
Through inducing cytokine signaling, BP1401 enhances T cell infiltration into tumor sites, i.e., turning cold tumors into hot tumors (T cell-rich tumors).
BP1401 is a lipid-nucleic acid drug in which a lipid-based drug delivery system is adopted.